Ignite Creation Date:
2024-05-06 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 12:54 PM
Study NCT ID:
NCT03677336
Status:
COMPLETED
Last Update Posted:
2020-12-17
First Post:
2018-09-04
Brief Title:
Oral Dydrogesterone OD Versus Micronized Vaginal Progesterone MVP for Luteal Phase Support LPS in IVFICSI
Sponsor:
CRG UZ Brussel
Organization:
CRG UZ Brussel
Study Overview
Official Title:
Oral Dydrogesterone Versus Micronized Vaginal Progesterone for Luteal Phase Support in In Vitro Fertilisation IVF IntraCytoplasmic Sperm Injection ICSI Pharmacokinetics and the Impact on the Endometrium the Microbiota of the Genital Tract and the Peripheral Immunology Double Blind Crossover Study
Status:
COMPLETED
Status Verified Date:
2020-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Female inability to conceive a child The purpose of this prospective randomized double-blinded double dummy two-arm cross-over study is to investigate the difference on histological transcriptional and immunological level in endometrium between 3x10mg Dydrogesterone oral tablets and 3x200 mg Micronized progesterone intravaginal capsules for the luteal support in egg cell donors Beside that the pharmacokinetics the impact on the peripheral immunology by blood sampling and the microbiota by genital swabs will be investigated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2018-000105-23 | EUDRACT_NUMBER | None | None |